NCT07012031View on ClinicalTrials.gov

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 24, 2025

Primary Completion Date

June 14, 2027

Study Completion Date

June 14, 2027

Conditions
Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Sotorasib

Given PO

BIOLOGICAL

Trastuzumab Deruxtecan

Given IV

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH